Wells Fargo & Company Nymox Pharmaceutical Corp Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.33 - $0.5 $66 - $100	200 Added 6.46%	3,296 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.28 - $0.74 $3,191 - $8,433	-11,397 Reduced 78.64%	3,096 $0
Q3 2022 Nov 14, 2022	BUY	$0.22 - $0.61 $3,188 - $8,840	14,493 New	14,493 $6,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.0 $9,048 - $14,956	-7,478 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.46 - $2.48 $321,362 - $545,875	-220,111 Reduced 96.71%	7,478 $12,000
Q1 2021 May 13, 2021	BUY	$2.22 - $3.39 $425,505 - $649,757	191,669 Added 533.6%	227,589 $506,000
Q4 2020 Feb 09, 2021	BUY	$1.84 - $2.83 $20,562 - $31,625	11,175 Added 45.16%	35,920 $90,000
Q3 2020 Nov 05, 2020	BUY	$2.3 - $3.66 $7,307 - $11,627	3,177 Added 14.73%	24,745 $61,000
Q2 2020 Aug 13, 2020	BUY	$2.1 - $4.6 $45,292 - $99,212	21,568 New	21,568 $76,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.